Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1990 3
1992 2
1993 5
1994 4
1995 2
1996 3
1997 4
1998 3
1999 8
2000 10
2001 4
2002 14
2003 7
2004 11
2005 11
2006 17
2007 16
2008 11
2009 9
2010 12
2011 10
2012 12
2013 18
2014 23
2015 16
2016 24
2017 21
2018 13
2019 12
2020 21
2021 27
2022 28
2023 26
2024 22
2025 28
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

420 results

Results by year

Filters applied: . Clear all
Page 1
2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease.
Hoang TD, Stocker DJ, Chou EL, Burch HB. Hoang TD, et al. Endocrinol Metab Clin North Am. 2022 Jun;51(2):287-304. doi: 10.1016/j.ecl.2021.12.004. Epub 2022 May 11. Endocrinol Metab Clin North Am. 2022. PMID: 35662442 Free PMC article. Review.
The management of hyperthyroidism and extrathyroidal manifestations of Graves disease remains complex. Considerations that include patient preference, age, comorbidity, pregnancy, tobacco smoking, and social determinants of health must all be weaved into a cohesive …
The management of hyperthyroidism and extrathyroidal manifestations of Graves disease remains complex. Considerations that include pa …
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM; EUGOGO †. Bartalena L, et al. Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67. doi: 10.1530/EJE-21-0479. Eur J Endocrinol. 2021. PMID: 34297684 Free article.
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease (GD). ...Early referral to specialized centers is fundamental for most patients with GO. Risk factors include smoking, thyroid dysfunction, high serum level of thyrotropin re …
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease (GD). ...Early referral to specialized ce …
[Graves' ophthalmopathy].
Eckstein A, Dekowski D, Führer-Sakel D, Berchner-Pfannschmidt U, Esser J. Eckstein A, et al. Ophthalmologe. 2016 Apr;113(4):349-64; quiz 465-6. doi: 10.1007/s00347-016-0239-3. Ophthalmologe. 2016. PMID: 27059986 Review. German.
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease and the full clinical picture can impair the quality of life of the patients considerably. ...Very important is the control of risk factors (smoking cessation, good control o …
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease and the full clinical picture can impair …
Current concepts regarding Graves' orbitopathy.
Bartalena L, Tanda ML. Bartalena L, et al. J Intern Med. 2022 Nov;292(5):692-716. doi: 10.1111/joim.13524. Epub 2022 Jun 1. J Intern Med. 2022. PMID: 35604323 Free PMC article. Review.
Graves' orbitopathy (GO) is an orbital autoimmune disorder and the main extrathyroidal manifestation of Graves' disease, the most common cause of hyperthyroidism. ...Original articles, clinical trials, systematic reviews, and meta-analyses from 1980 to 2021 were sea …
Graves' orbitopathy (GO) is an orbital autoimmune disorder and the main extrathyroidal manifestation of Graves' disease, the m …
Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management.
Wiersinga WM, Eckstein AK, Žarković M. Wiersinga WM, et al. Lancet Diabetes Endocrinol. 2025 Jul;13(7):600-614. doi: 10.1016/S2213-8587(25)00066-X. Epub 2025 May 2. Lancet Diabetes Endocrinol. 2025. PMID: 40324443 Review.
Thyroid eye disease (TED; also known as Graves' orbitopathy), causes swollen extraocular muscles and orbital fat. Mechanistically, TED involves lid retraction, oedema and redness of the eyelids and conjunctiva, proptosis, diplopia, and optic neuropathy. ...TED is predomina …
Thyroid eye disease (TED; also known as Graves' orbitopathy), causes swollen extraocular muscles and orbital fat. Mechanistically, TE …
Relationship between cigarette smoking and Graves' ophthalmopathy.
Hegediüs L, Brix TH, Vestergaard P. Hegediüs L, et al. J Endocrinol Invest. 2004 Mar;27(3):265-71. doi: 10.1007/BF03345276. J Endocrinol Invest. 2004. PMID: 15165003 Review.
Environmental triggers in the development of Graves' disease (GD) have been suggested from the very first description of the disease. Since 1987 a number of studies from various countries, have assessed the risk for Graves' ophthalmopathy (GO) associated with …
Environmental triggers in the development of Graves' disease (GD) have been suggested from the very first description of the disease. …
Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy.
Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Bartalena L, et al. Front Endocrinol (Lausanne). 2020 Nov 30;11:615993. doi: 10.3389/fendo.2020.615993. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33329408 Free PMC article. Review.
GO is the most frequent extrathyroidal manifestation of Graves' disease, although it may rarely occur in euthyroid/hypothyroid patients with chronic autoimmune thyroiditis. ...The prevalence of GO is lower than in the past among patients with recent onset Graves' hy …
GO is the most frequent extrathyroidal manifestation of Graves' disease, although it may rarely occur in euthyroid/hypothyroid patien …
Management of Graves' ophthalmopathy.
Wiersinga WM. Wiersinga WM. Nat Clin Pract Endocrinol Metab. 2007 May;3(5):396-404. doi: 10.1038/ncpendmet0497. Nat Clin Pract Endocrinol Metab. 2007. PMID: 17452966 Review.
Management of Graves' ophthalmopathy is preferably done in a multidisciplinary setting. Smoking is associated with worse disease outcome. (131)I therapy for hyperthyroidism can also worsen ophthalmopathy, especially if administered during active diseas …
Management of Graves' ophthalmopathy is preferably done in a multidisciplinary setting. Smoking is associated with wors …
Treating severe Graves' ophthalmopathy.
Bartalena L, Marcocci C, Pinchera A. Bartalena L, et al. Baillieres Clin Endocrinol Metab. 1997 Oct;11(3):521-36. doi: 10.1016/s0950-351x(97)80738-0. Baillieres Clin Endocrinol Metab. 1997. PMID: 9532337 Review.
A minority of patients (3-5%) have severe Graves' ophthalmopathy, for which the three main treatment procedures are represented by high-dose glucocorticoids, orbital radiotherapy and orbital decompression. ...Smoking deleteriously influences the course of …
A minority of patients (3-5%) have severe Graves' ophthalmopathy, for which the three main treatment procedures are represente …
420 results